Strep throat | Top 7 novel treatment findings

Maternal vaccination against Group B Streptococcus reduces infant disease risk

Higher infant IgG titres against GBS surface proteins were associated with a significant reduction in the risk of invasive GBS disease, with an adjusted disease risk reduction of ≥80% for strains expressing homotypic proteins.

Study published: 2024-07-21

Screening pregnant women for Group B Streptococcus reduces infant infections.

Women generally express positive attitudes towards GBS testing, viewing it as a protective measure for their babies. High levels of acceptability for GBS testing have been reported, with many women preferring universal screening strategies.

Study published: 2024-06-28

Antibiotic treatment reduces severe Group A strep infections in children

The study found a significant increase in the recording of GAS cases and associated antibiotic prescriptions, with peaks in December 2022 surpassing previous years. This indicates effective identification and treatment of GAS infections during the outbreak.

Study published: 2023-09-23

Azithromycin reduces GAS carriage

The treatment significantly reduced GAS carriage in breast milk (0.28% vs 2.48%) and nasopharynx (0.28% vs 1.93%) among mothers, and also showed a slight reduction in neonates' nasopharyngeal carriage (0.57% vs 1.91%).

Study published: 2020-12-07

Antibiotic treatment reduces multidrug-resistant bacteria in otitis media patients

The study found a high prevalence of multidrug-resistant bacterial pathogens in patients with otitis media, emphasizing the need for appropriate antibiotic selection to improve treatment outcomes.

Study published: 2024-04-03

BNO 1030 reduces antibiotic need in children with severe tonsillitis

BNO 1030 significantly reduced symptom severity, improved self-assessment of symptoms, and decreased the need for antibiotic prescriptions by 43.7%.

Study published: 2021-03-12

Intranasal live attenuated influenza vaccine increases Streptococcus pyogenes colonization in children aged 24-59 months.

Increased colonization rates of S. pyogenes in the LAIV group compared to controls, with a significant odds ratio indicating a higher likelihood of colonization post-vaccination.

Study published: 2022-11-29